Guardant Health (GH) Q3 2026 earnings review
Guardant's screening sales nearly triple, but its net loss widens
Guardant Health, which sells blood tests that find and track cancer, now grows mainly through its colon-cancer screening test. Shield revenue rose 180%, while sales of tests for patients already diagnosed grew a slower 25%. The company raised its yearly sales outlook a third time, but by our math growth eases to about 31% in the fourth quarter.
| Sales growth, excluding revenue for earlier periods' tests | 42% 36% as reported |
|---|---|
| Shield tests | 83,000 24,000 a year ago |
| Loss per share, excluding one-offs | $0.29 $0.39 a year ago |
| Full-year revenue outlook | Raised to $1.36–1.37B middle of the range: 39% growth |
⚖️ Verdict: 🟢 Bullish
The story got better, because Shield's volume and cost per test both beat the company's own plan. Its cost per test fell to $330, below the year-end target, so each screening test now earns more. The bad news: Guardant's other cancer tests bring in less per test, and it widened its spending and cash-burn plans again.
The question now is whether Shield's price per test holds as more privately insured patients under 65 arrive. Either new insurer contracts lift the price after a small dip, or insurers pay less and screening keeps losing money for longer. Results for the first half of 2027, with full UnitedHealth coverage, will tell.
🐂 Bull Case
Shield Tests More Than Tripled as Coverage Widened
Shield, Guardant's blood test for colon cancer, is the company's main growth bet. Co-chief executive AmirAli Talasaz said volume came in "above our expectation". He credited "improved productivity of our reps" and a national advertising campaign.
- Shield tests: about 83,000, against 24,000 a year ago
- Step from last quarter: 17,000 tests, against 8,000 a year earlier
- People covered for Shield: about 100 million from January, up from about 70 million
Insurers also widened access during the quarter. UnitedHealth began covering Shield in August. Carelon and EviCore, which manage benefits for other insurers, adopted policies that start in November and January.
This matters because doctors order a test more readily when the patient's insurer pays for it. But Talasaz said the coverage is going to "take some time for it to really show itself in our numbers". So the sales force, not the new coverage, produced most of this quarter's step.
What to watch: the step in Shield tests from the third to the fourth quarter, reported in early 2027. A step above this quarter's 17,000 would show coverage adding demand on top of the sales force.
Shield's Cost per Test Fell Ahead of Plan
Shield, Guardant's colon-cancer blood test, lost money on each test at launch, so lab cost decides whether screening pays. In August the lab switched to a cheaper workflow that the FDA approved in July.
Cost per Shield test fell to $330 from $410 in the spring. Finance chief Mike Bell said that beat the year-end target of $350, arriving "a full quarter ahead of schedule".
The cost of running tests, excluding one-offs, dropped 0.8 percentage points to 33.5% of revenue. Bell said cheaper tests offset a shift toward Shield and Reveal, so gross margin held above what the old outlook implied. That says the plan was cautious.
What to watch: Shield cost per test in the fourth quarter. Bell expects scale gains first, then an automated lab in Palo Alto, on the way to a $200 goal by the end of 2028.
Guardant360 Won Approval for Repeat Breast Cancer Testing
Guardant360 is the company's blood test that reads tumor DNA to help doctors pick a drug. Co-chief executive Helmy Eltoukhy said "most physicians are still really only profiling their patients once for a lifetime".
In September the FDA approved Guardant360 CDx to track ESR1, a gene change showing breast cancer resists treatment, for AstraZeneca's camizestrant. The approved protocol recommends a test every three months. Guardant360 Liquid volume also grew nearly 30%, Eltoukhy said.
This matters because a test repeated every three months earns several payments per patient, not one. But Medicare's coverage rules do not yet pay for quarterly testing, Eltoukhy said, so a partnership with drugmakers covers patients until Medicare updates them.
What to watch: Guardant360 Liquid volume growth in 2027, when comparisons get harder. It will show whether repeat testing brings in extra tests rather than shifting existing ones.
Positives this quarter didn't test
Four standing positives got no hard test this quarter, because the numbers that would test them arrive later. Each item below names the reading that would move it.
- Reveal Ultra, a more sensitive test for cancer left after surgery: launched for drug companies; the clinical launch by year-end starts its revenue.
- Multi-cancer results on Shield: more doctors opt in, co-chief executive AmirAli Talasaz said, but Guardant gives no rate.
- Cash flow outside screening: positive for 2026, finance chief Mike Bell said; full-year results in early 2027 will confirm it.
- Company-wide cash break-even by the end of 2027: reaffirmed by Bell; quarterly burn next year will show the path.
🐻 Bear Case
Oncology Tests Grew 58%, Revenue Only 25%
Oncology, Guardant's tests for people already diagnosed with cancer, earns nearly two-thirds of revenue. Co-chief executive Helmy Eltoukhy credited 58% volume growth to "broad contributions across our portfolio".
Sales lagged behind tests. Oncology revenue rose 25%, the slowest of the last five quarters. By our math, revenue per test fell about 21% from a year ago and 6% from the spring.
A year ago Guardant also booked $16.8 million for tests from earlier periods, which makes the comparison harder. Finance chief Mike Bell said prices for each main test stayed "broadly stable" from last quarter. So by our math, the mix of tests explains the drop since spring.
Reveal, the test that tracks whether cancer returns, more than doubled its volume again. That growth is the case for Reveal as Guardant's next big product. But Medicare's MolDX program, which rules on coverage for genetic tests, still reviews Reveal for breast cancer and for tracking treatment.
The new outlook lifted oncology volume but kept revenue growth unchanged, so by our math it builds in a further fall in revenue per test. What to watch: MolDX decisions on Reveal, pending for more than a year. Approval would turn tests already run into paid ones.
Shield's Price Faces Pressure From Younger Patients
Shield, the colon-cancer blood test, earns most of its revenue from Medicare and Medicare Advantage plans. Commercial insurers pay little until Guardant can show a record of collections, so more patients under 65 lower the average price.
For now the price held. By our math Shield earned about $815 per test, against $801 last quarter and above what the old outlook implied. Finance chief Mike Bell credited better Medicare Advantage payments.
But Bell expects the price to "tick down a little" as commercially insured patients arrive, with $700 as the floor. Co-chief executive AmirAli Talasaz said a UnitedHealth contract "takes some time". By our math, the new full-year plan implies about $777 per test in the fourth quarter.
What to watch: Shield revenue per test in the fourth quarter, reported in early 2027. A figure well below $777 would leave volume to carry screening's growth alone.
Losses Widened as Spending and Legal Costs Rose
Finance chief Mike Bell still targets company-wide cash break-even by the end of 2027. Yet the net loss widened 34%, to $124 million, although the loss excluding one-offs narrowed.
Overhead drove the gap. General and administrative costs rose 5.1 percentage points to 25.2% of revenue. Legal bills alone added $22.6 million. In its patent fight with TwinStrand Biosciences, a US patent board ruled in October that Guardant had not proved TwinStrand's claims invalid. Guardant now puts its possible loss at up to $270 million.
The outlook moved the same way. Guardant raised its spending plan a third time and widened its cash-burn range, partly because of a Medicare billing delay. Bell said the company will keep "reinvesting incremental gross profit" in Shield.
What to watch: full-year free cash flow, due in early 2027. A burn inside the new range keeps the 2027 break-even target within reach.
Risks this quarter didn't answer
Five standing risks got little new evidence this quarter. Each item below names the disclosure that would move it, and most of those disclosures arrive in 2027.
- Federal billing inquiry: prosecutors in Florida sought documents in April on bills to government health plans under the False Claims Act; the filing adds nothing new.
- Premium Medicare price for Guardant360 Liquid CDx: Guardant filed for ADLT status, Medicare's higher rate for advanced lab tests, and expects a decision in the first half of 2027.
- Convertible bonds: holders of the 2031 and 2033 notes may convert until December 31, but none had asked by October 30.
- Rival tests for cancer left after surgery: Reveal Ultra launches for doctors by year-end; early orders will show whether it wins share.
- Drug-company revenue: up 8%, the slowest in five quarters; the full-year plan needs a faster fourth quarter.
👓 Other Themes
Pennsylvania Acts While Federal Screening Panel Stays Idle
Pennsylvania passed a law that lets residents get blood-based colon cancer screening without paying out of pocket, co-chief executive AmirAli Talasaz said. He added that the US Preventive Services Task Force, whose advice shapes what insurers must cover, had not met in two years. Guardant is working on similar bills in other large states.
💲 Other KPIs
Money owed to Guardant jumped $42 million in the quarter, faster than sales rose. By our math, collecting a quarter's revenue now takes about 48 days, against 39 in the spring. A year ago it took 40. Finance chief Mike Bell said Medicare cannot yet process claims for Guardant360 Liquid CDx, which holds back some payments.
The share count rose 7.7% from a year ago, and the pace has quickened in each of the last three quarters. Last November's share sale and stock pay for staff explain it. Stock pay reached $62.4 million in the quarter, up 46%, so any future profit spreads over more shares.
Deferred revenue, cash drug companies paid upfront for work not yet done, fell for a third straight quarter. The current portion stood at $38.1 million, against $50.8 million in December. Guardant turned $42.9 million of the year-start balance into revenue this year and refilled less of it.
🔮 Guidance
Raised. The plan now has sales growing 38% to 40% this year. Guardant has lifted it three times in 2026, each time by less. The middle of the range moved +$45M, +$40M, then +$15M. Even so, the remaining quarter looks slower. By our math, the plan leaves about 31% growth for the fourth quarter. That is down from 36% in the third.
Unchanged. The forecast still has sales of tests for diagnosed patients up about 30% for the year. By our math, that leaves about 23% growth for the fourth quarter, the slowest of 2026. Last year's fourth quarter grew 30%, so the comparison stays hard.
Raised. The plan calls for oncology test volume to grow more than 50% this year. Through nine months, volume rose about 56% by our math. Meeting the target therefore needs only about 35% growth in the fourth quarter, against 58% in the third. Because revenue growth stayed put, revenue per test keeps falling in the plan, by our math.
Unchanged. The outlook still has revenue from drug-company work growing at a low double-digit rate. Through nine months it rose about 11%. By our math, the year then needs about 12% growth in the fourth quarter, against 8% in the third. Milestone payments tied to drug approvals drove growth earlier this year, the filing said.
Raised for a third time this year. Steps at the middle of the range ran +$24M, +$32M, then +$11.5M. By our math, the forecast leaves about $73 million of Shield revenue for the fourth quarter. That would roughly double last year's fourth quarter, a slower rise than the third quarter's.
Raised. The plan now centres on about 287,500 Shield tests for the year. By our math, that leaves about 94,500 for the fourth quarter. The step from the third quarter would be 11,500 tests, smaller than the third quarter's own step, while new insurer coverage phases in.
Raised to the top of the old range. Through nine months the margin ran about 66.5%. By our math, a 65% year leaves the fourth quarter near 61%. Rounding could lift that to about 63%. Finance chief Mike Bell cited a shift in product mix toward Shield and Reveal, offset by cheaper tests.
Raised for a third time. Steps at the middle ran +$20M, +$30M, then +$25M. Bell said Guardant keeps putting extra gross profit into building Shield sales. By our math, the range leaves about $271 million for the fourth quarter, below the third quarter's $287 million. Full-year spending growth stays in the low twenties.
Wider burn, for a second time this year. Bell said Medicare cannot process Guardant360 Liquid CDx claims until January, so $10 million to $15 million of payments slip into 2027. Without that delay, he said, the plan would be unchanged. By our math, the range implies about $35 million of fourth-quarter burn, against $54 million a year earlier.
❓ Key Questions
What share of Shield tests include multi-cancer results?
Co-chief executive AmirAli Talasaz says more doctors opt in to multi-cancer reports, but Guardant has given no rate for three quarters. The rate sizes the data it needs for FDA approval of its multi-cancer test.
How much revenue does Reveal bring in?
Reveal is the fastest-growing oncology test, yet Guardant gives no revenue or test count for it. Without them, readers cannot tell how much Reveal explains the fall in oncology revenue per test.
What does UnitedHealth pay for a Shield test?
UnitedHealth coverage started in August, and Talasaz said contract talks have only begun. The answer decides whether Shield's price stays near current levels or drifts toward the $700 floor finance chief Mike Bell named.
Does the TwinStrand royalty sit inside the margin outlook?
A court granted TwinStrand an ongoing 6% royalty in June, and Guardant has paid nothing so far. Readers need to know whether the full-year gross margin plan already absorbs that cost.
Will the 2027 outlook keep the 2028 revenue goal?
Guardant set a $2.2 billion revenue goal for 2028 but did not restate it this quarter. The 2027 plan, due with fourth-quarter results, will show whether the company still sees that path.